Faculty Profiles - MIZUNO, Masashi

Papers - MIZUNO, Masashi

Division display 281 - 300 of about 343 ／ All the affair displays >>

The use of polysulfone hemodialysis membrane may improve hyperlipemia in patients receiving long-term maintenance hemodialysis Reviewed

MIZUNO Masashi, KOBAYASHI Kaoru, NAKATA Atsuhiro, WATANABE Midoriko, TORIYAMA Takanobu, KAWAHARA Hirohisa, MATSUO Seiichi

Vol. 35 ( 1 ) page： 43 - 49 2002.1

Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following lipopolysaccharide priming

Mizuno M, Nishikawa K, Okada N, Matsuo S, Okada H

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY Vol. 127 ( 1 ) page： 55 - 62 2002.1

Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following lipopolysaccharide priming.

Mizuno M, Nishikawa K, Okada N, Matsuo S, Okada H

International archives of allergy and immunology Vol. 127 ( 1 ) page： 55 - 62 2002.1

高脂血症を伴う長期維持血液透析患者におけるポリスルフォン膜(PS-UW)の有用性について Reviewed

水野正司、小林薫、中田淳博、渡辺緑子、鳥山高伸、川原弘久、松尾清一

日本透析医学会雑誌 Vol. 35 page： 43-49 2002

二次性副甲状腺機能亢進症に対するmaxacalcitorol（オキサロールＲ）静注パルス療法の効果 ―早期低用量使用の試みー Reviewed

渡辺緑子、中田敦博、八島影人、河出恭雅、佐藤悌、小杉智規、鳥山高伸、河原弘久、水野正司、森田良樹、松尾清一

日本透析医学会誌 Vol. 35 page： 1193-1250 2002

Soluble CR1 protects rats from lethal shock induced by anti-Crry antibody following LPS priming. Reviewed

Mizuno M., Nishikawa K., Okada N., Mastuo S., Okada H.

Internal. Arch. Allergy Immunol. Vol. 127 page： 55-62 2002

Nephrogenic diabetes insipidus associated with hemochromatosis. Reviewed

Okumura A., Kondo K., Hirai C., Nishimura H., Tamai H., Kawarazaki F., Ichikaraki M., Mizuno M., Oiso Y., Yamamoto M.

Am J Kidney Dis Vol. 40 page： 403-406 2002

P-selectin-dependent macrophage migration into the tubulointerstitium in unilateral ureteral obstruction. Reviewed

Naruse T., Yuzawa Y., Akahori T, Mizuno M., Maruyama S., Kannagi R., Hotta S., Matsuo S.

Kidney Int. Vol. 62 page： 94-105 2002

The effects of low-dose intravenous maxacalcitol therapy on mild secondary hyperparathyroidism. Reviewed

Watanabe Midoriko, Nakata Atsuhiro, Yashima Akihito, Kawade Yasumasa, Sato Yasushi, Kosugi Tomoki, Toriyama Takanobu, Kawahara Hirohisa, Mizuno Masashi, Morita Yoshiki, Matsuo Seiichi

Nihon Toseki Igakkai Zasshi Vol. 35 ( 8 ) page： 1193 - 1198 2002

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society for Dialysis Therapy

This study evaluated the effects of low-dose i. v. maxacalcitol (OXAROL<sup>®</sup> OCT) in controlling mild secondary hyperparathyroidism (II° HPT) in chronic hemodialysis patients. Nineteen patients were selected for treatment because of increased parathyroid hormone (PTH) levels de spite administration of vitamin D (VD). The patients consisted of 15 males and 4 females, and were divided into 2 groups based on serum intact-PTH (i-PTH) levels (group I; N=11, 240pg/mL≤i-PTH<360pg/mL, group II; N=8, 360pg/mL≤i-PTH<500pg/mL). After a 2-week wash-out period for oral VD, OCT was given intravenously at a dose of 2.5μg in group I and 5.0μg in group II at the end of dialysis therapy 3 times/week. The dose was adjusted to maintain serum i-PTH levels at 240-500pg/mL and normal calcium (Ca) levels. During the 48-week observation period, serum i-PTH decreased significantly in both groups. Serum Ca levels increased mildly in both groups, but they remained within the normal range. Serum levels of phosphorus, ALP, bone ALP and osteocalcin were not significantly changed in either group. There was no correlation between parathyroid gland volume and i-PTH level. These findings suggest that long-term intravenous treatment with low-dose OCT is a useful strategy for the treatment of mild II° HPT without significant increase of serum Ca.

DOI： 10.4009/jsdt.35.1193

CiNii Research

The use of polysulfone hemodialysis membrane may improve hyperlipemia in patients receiving long-term maintenance hemodialysis. Reviewed

Mizuno Masashi, Kobayashi Kaoru, Nakata Atsuhiro, Watanabe Midoriko, Toriyama Takanobu, Kawahara Hirohisa, Matsuo Seiichi

Nihon Toseki Igakkai Zasshi Vol. 35 ( 1 ) page： 43 - 49 2002

Authorship：Lead author,　Corresponding author Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society for Dialysis Therapy

Ischemic heart disease, cerebral hemorrhage, and cerebral embolus are severe complications seen in patients on maintenance hemodialysis. Hyperlipidemia is one of the risk factors profoundly associated with these complications. We investigated whether the use of polysulfone (PS) hemodialysis membrane improved serum levels of some lipid components in 6 non-DM patients on long-term maintenance hemodialysis. These 6 non-DM patients (one treated with CTA-membrane, 5 with EVAL-membrane) had hyperlipidemia (total cholesterol (TC) 263±17mg/dL, triglyceride (TG) 176±20mg/dL). Three patients were administered 5mg/day of Pravastatin sodium as an anti-hyperlipidemic drug, and one received 20mg/day of the same drug. We measured serum levels of TC, TG, LDL-C, HDL-C, LDL-TG, HDL-TG, Apo-A1, Apo-C3 and other factors before and 1 week after, then 1, 3, 5 and 6 months after the change in hemodialysis membrane. The serum TC level started to decrease after changing the membrane, and it decreased to 212±8mg/dL 3 months after that. Serum levels of LDL-C, Apo-A1 and Apo-C3 had significantly decreased at 6 months after the use of PS-membrane. However, serum levels of HDL-C and TG saw no change after the use of PS-membrane.<br>In addition, we tried to decrease or stop anti-hyperlipidemic drugs 6 months after the change in hemodialysis membrane when serum levels of TC had decreased and remained under 200mg/dL. One of the subjects did not need any drugs associated with hyperlipidemia. Another needed to have an anti-hyperlipidemic drug readministered about 4 months after the drug had been stopped.<br>In the present study, the PS-membrane might improve the hyperlipidemic profiles in patients on long-term hemodialysis. It was suggested that the use of PS-membrane might be available to decrease the dosage of antihyperlipidemia drugs or stop the administration of these drugs in hyperlipidemic patients on maintenance hemodialysis.

DOI： 10.4009/jsdt.35.43

CiNii Research

高脂血症を伴う長期維持血液透析患者におけるポリスルフォン膜(PS-UW)の有用性について Reviewed

水野正司, 小林薫, 中田淳博, 渡辺緑子, 鳥山高伸, 川原弘久, 松尾清一

日本透析医学会雑誌 Vol. 35 page： 43-49 2002

二次性副甲状腺機能亢進症に対するmaxacalcitorol（オキサロールＲ）静注パルス療法の効果 ―早期低用量使用の試みー Reviewed

渡辺緑子, 中田敦博, 八島影人, 河出恭雅, 佐藤悌, 小杉智規, 鳥山高伸, 河原弘久, 水野正司, 森田良樹, 松尾清一

日本透析医学会誌 Vol. 35 page： 1193-1250 2002

Blockage of complement regulators in the conjunctiva and within the eye leads to massive inflammation and iritis Reviewed

DS Bardenstein, CJ Cheyer, C Lee, E Cocuzzi, M Mizuno, N Okada, ME Medof

IMMUNOLOGY Vol. 104 ( 4 ) page： 423 - 430 2001.12

Language：English Publishing type：Research paper (scientific journal) Publisher：BLACKWELL SCIENCE LTD

The open environment of the eye is continuously subject to an influx of foreign agents that can activate complement. Decay-accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 are regulators that protect self-cells from autologous complement activation on their surfaces. They are expressed in the eye at unusually high levels but their physiological importance in this site is unstudied. In the rat, a structural analogue termed 5I2 antigen (5I2 Ag) has actions overlapping DAF and MCP. In this investigation, we injected F(ab')(2) fragments of 5I2 mAb into the conjunctiva and aqueous humor, in the latter case with and without concomitant blockage of CD59. Massive neutrophilic infiltration of the stroma and iris resulted upon blocking 5I2 Ag activity. Frank necrosis of the iris occurred upon concomitant intraocular blockage of CD59. C3b was identified immunohistochemically, and minimal effects were seen in complement-depleted animals and in those treated with non-relevant antibody. The finding that block-age of 5I2 Ag function in periocular tissues and within the eye causes intense conjunctival inflammation and iritis demonstrates the importance of intrinsic complement regulators in protecting ocular tissues from spontaneous or bystander attack by autologous complement.

Web of Science

researchmap

Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats Reviewed International coauthorship International journal

M Mizuno, K Nishikawa, OB Spiller, BP Morgan, N Okada, H Okada, S Matsuo

ARTHRITIS AND RHEUMATISM Vol. 44 ( 10 ) page： 2425 - 2434 2001.10

Authorship：Lead author,　Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：WILEY-LISS

Objective. To investigate changes in the distribution patterns of membrane complement regulators (MCRs) during the development of type II collagen-induced arthritis (CIA) and to examine the protective effects of these molecules against the augmentation of CIA in the knee joint.
Methods. Immunohistochemistry was used to examine the distribution of the MCRs Crry, DAF, and CD59 in the synovium of knee joints before and 2, 4, and 10 weeks after induction of CIA by immunization with type II collagen. In addition, at 2 or 10 weeks after induction of CIA, rats were injected intraarticularly with anti-Crry and/or anti-CD59 as the F(ab')(2) fraction of monoclonal antibodies (mAb). Knee joint swelling and histologic changes in the synovium were examined 2 weeks after mAb injection.
Results. Synovial expression of Crry, DAF, and CD59 decreased in parallel with increased inflammation. When Crry and CD59 were functionally blocked at 2 weeks after the induction of CIA, swelling of the knee joints was markedly increased. Blocking of either regulator alone had no effect on swelling. Thickening of the synovial surface and proliferation of subsynovial tissue were all increased after blocking Crry and CD59, whereas blocking of either MCR alone had no effect. When both Crry and CD59 were blocked, deposits of membrane attack complex were found in the synovium.
Conclusion. Our findings indicate that in rats with CIA and severely inflamed synovium, local expression of MCR is reduced. The MCRs Crry and CD59 appear to suppress the development of CIA.

DOI： 10.1002/1529-0131(200110)44:10<2425::AID-ART407>3.0.CO;2-4

Web of Science

PubMed

researchmap

The role of C5a in the development of thrombotic glomerulonephritis in rats

Kondo C, Mizuno M, Nishikawa K, Yuzawa Y, Hotta N, Matsuo S

CLINICAL AND EXPERIMENTAL IMMUNOLOGY Vol. 124 ( 2 ) page： 323 - 329 2001.5

The role of C5a in the development of thrombotic glomerulonephritis in rats. Reviewed International journal

Kondo C, Mizuno M, Nishikawa K, Yuzawa Y, Hotta N, Matsuo S

Clinical and experimental immunology Vol. 124 ( 2 ) page： 323 - 9 2001.5

Glomerulocystic kidney associated with subacute necrotizing-encephalomyelopathy Reviewed International journal

T Yamakawa, F Yoshida, T Kumagai, H Watanabe, A Takano, M Mizuno, H Ikeguchi, Y Morita, G Sobue, S Matsuo

AMERICAN JOURNAL OF KIDNEY DISEASES Vol. 37 ( 2 ) page： E14 2001.2

Language：English Publishing type：Research paper (scientific journal) Publisher：W B SAUNDERS CO

A 22-year-old man with subacute necrotizing-encephalomyelopathy (SNE; Leigh's disease) was diagnosed as having progressive renal dysfunction. The clinical diagnosis of Leigh's disease was obtained by the typical central nervous lesions, abnormalities in other organs, and increased lactate concentrations in blood and cerebrospinal fluid. We performed an open biopsy of the right kidney. Light microscopic studies of the renal specimen showed diffuse glomerulocystic kidney (GCK) with tubulointerstitial damage. Electron microscopic examination showed marked swelling and increase in the number of mitochondria of the renal tubular epithelial cells. Therefore, it is suggested that mitochondrial disease seems to play an important role in developing GCK. (C) 2001 by the National Kidney Foundation, Inc.

DOI： 10.1053/ajkd.2001.21358

Web of Science

PubMed

researchmap

【Innate immunity】　臨床　補体制御因子と疾患 Reviewed

松尾清一, 水野正司

現代医療 Vol. 33 page： 1011-1016 2001

Membrane complement regulators protect against the development of type II collagen-induced arthritis (CIA) in rats. Reviewed

Mizuno M., Nishikawa K., Spiller OB., Morgan BP., Okada N., Okada H., Matsuo S.

Arthritis Rheum. Vol. 44 page： 2425-2434 2001

The effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis. Reviewed

Ito I., Yuzawa Y., Mizuno M., Nishikawa K., Jomori T., Tashita A., Hotta N., Matsuo S.

Am. J. Kidney Dis. Vol. 38 page： 265-273 2001

　 PREV - NEXT 　

<MIZUNO, Masashi>

Papers - MIZUNO, Masashi